Article
CYP450 polymorphisms predict clinic outcomes to vinorelbine-based chemotherapy in patients with non-small-cell lung cancer.
Acta oncologica (Stockholm, Sweden) - 1 Jan 2007
Pan Ji-Hong, Han Jin-Xiang, Wu Jian-Mei, Sheng Li-Jun, Huang Hai-Nan
Abstract excerpt
CYP2C19*2(G681A), CYP2C19*3(G636A), CYP2D6*4(C188T), CYP2D6*2(C2938T, G4268C), CYP3AP1*3- G44A and CYP3A5*3(A22893G) are the most common polymorphisms detected among Chinese that may influence the efficacy of vinorelbine-based therapies to treat non-small-cell lung cancer (NSCLC). We detected the genotypes of these polymorphisms by PCR-RFLP in 59 patients with NSCLC and assessed their responses to vinorelbine....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.